Pages that link to "Q39523831"

The following pages link to The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis (Q39523831):

Displaying 28 items.

• Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage (Q30300218) (← links)
• Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis (Q33579016) (← links)
• Development of a dimethylarginine dimethylaminohydrolase (DDAH) assay for high-throughput chemical screening (Q34213198) (← links)
• Hypoxia-induced deoxycytidine kinase contributes to epithelial proliferation in pulmonary fibrosis. (Q34987189) (← links)
• A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxide (Q35019853) (← links)
• Developing an irreversible inhibitor of human DDAH-1, an enzyme upregulated in melanoma. (Q35031641) (← links)
• Metabonomic analysis of potential biomarkers and drug targets involved in diabetic nephropathy mice (Q35824916) (← links)
• Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis (Q35908085) (← links)
• Altered DNA methylation profile in idiopathic pulmonary fibrosis (Q36345274) (← links)
• Dimethylarginine dimethylaminohydrolase 2 promotes tumor angiogenesis in lung adenocarcinoma (Q36651307) (← links)
• Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. (Q37607150) (← links)
• Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators? (Q37684919) (← links)
• The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis (Q38055449) (← links)
• The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases. (Q38203518) (← links)
• Proton pump inhibitors in IPF: beyond mere suppression of gastric acidity. (Q38959380) (← links)
• Selective Covalent Protein Modification by 4-Halopyridines through Catalysis. (Q40226850) (← links)
• Anti-acid treatment for idiopathic pulmonary fibrosis. (Q45190301) (← links)
• Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux (Q47417631) (← links)
• Restoration of Megalin-Mediated Clearance of Alveolar Protein as a Novel Therapeutic Approach for Acute Lung Injury (Q47842866) (← links)
• FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis (Q48156634) (← links)
• Metabolomics diagnostic approach to mustard airway diseases: a preliminary study. (Q49243371) (← links)
• Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model (Q50676736) (← links)
• Live and let die: targeting alveolar epithelial cell proliferation in pulmonary fibrosis. (Q55069364) (← links)
• DDAH2 alleviates myocardial fibrosis in diabetic cardiomyopathy through activation of the DDAH/ADMA/NOS/NO pathway in rats (Q61444486) (← links)
• Dissection, Optimization, and Structural Analysis of a Covalent Irreversible DDAH1 Inhibitor (Q89459978) (← links)
• The Second Life of Methylarginines as Cardiovascular Targets (Q90163907) (← links)
• Proton Pump Inhibitors and Osteoporosis: Is Collagen a Direct Target? (Q98465424) (← links)
• Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review (Q99634847) (← links)